HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
Rhea-AI Summary
HCW Biologics (NASDAQ: HCWB) reported Q1 2026 revenue of $6.5 million, driven by an exclusive worldwide license for HCW11-006 to Trimmune, and net income of $3.5 million. R&D and G&A expenses declined 15% and 18% year-over-year.
The company remains on track for preliminary Phase 1 data for HCW9302 in alopecia areata in 1H 2026, with full readout expected in Q4 2026, and reported no dose-limiting toxicities to date. A Science Advances publication highlighted HCW9206 as a potential CAR-T manufacturing reagent.
HCW completed a $1.5 million equity financing in February 2026. Management notes substantial doubt about going-concern status without additional funding, and HCW is appealing a Nasdaq delisting notice related to the $1.00 minimum bid price rule.
AI-generated analysis. Not financial advice.
Positive
- Q1 2026 revenue rose to $6.5 million, primarily from the Trimmune license
- Trimmune license delivered $3.5 million cash and $3.5 million equity upfront
- Q1 2026 net result improved to $3.5 million income from a prior-year loss
- R&D expenses decreased 15% year-over-year to $1.3 million
- G&A expenses decreased 18% year-over-year to $1.8 million
- Published data on HCW9206 support partnering opportunities in CAR-T manufacturing reagents
Negative
- Substantial doubt disclosed about ability to continue as a going concern without new funding
- Nasdaq minimum $1.00 bid price non-compliance risks potential delisting of HCWB shares
- February 2026 financing and warrant repricing imply potential shareholder dilution if exercised
- Q1 revenues remain entirely license-based, highlighting dependence on external partners
- Ongoing costs expected to comply with obligations under a Settlement and Release Agreement
News Market Reaction – HCWB
On the day this news was published, HCWB gained 262.02%, reflecting a significant positive market reaction. Argus tracked a peak move of +284.5% during that session. Our momentum scanner triggered 60 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $9.53M at that time. Trading volume was exceptionally heavy at 68.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Among close biotech peers, moves are mixed: AIM -7.73%, BCLI -0.87%, PMCB +14.52%, TNFA -9.72%, CYCN flat. Only one momentum-peer (ALZN +1.90%) screened, suggesting stock-specific drivers for HCWB.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Q4/FY 2025 results | Negative | -16.7% | Full-year 2025 results with low revenue, improved loss and going-concern doubts. |
| Nov 14 | Q3 2025 results | Negative | +2.0% | Q3 2025 results, new financing and continued going-concern and Nasdaq issues. |
| Aug 18 | Q2 2025 results | Positive | -1.7% | Q2 2025 update with equity raise, debt extinguishment and potential license fee. |
| May 15 | Q1 2025 results | Positive | +9.2% | Q1 2025 results, equity offering, FDA clearance and expected license fee. |
| Mar 28 | FY 2024 results | Negative | -0.8% | FY 2024 update with larger net loss and Nasdaq compliance challenges. |
Earnings releases have produced a modest average next-day move of -1.61%, with mixed alignment between fundamentals and price, and recurring going-concern and Nasdaq compliance themes.
Across the last five earnings events from Mar 2024–Mar 2026, HCW Biologics repeatedly combined pipeline updates for HCW9302 and licensing deals with ongoing capital raises and going-concern language. Revenues remained low but improved in late 2025, while net losses narrowed versus prior years. Nasdaq listing compliance and reverse-split or equity-raise tools have been recurring topics. Today’s Q1 2026 update continues the pattern of financing plus clinical and licensing progress under balance-sheet pressure.
Historical Comparison
In the past five earnings releases, HCWB’s average next-day move was -1.61%, with frequent references to going-concern doubts and Nasdaq listing risk alongside financing and pipeline updates.
Earnings updates have tracked HCW9302 from FDA clearance into Phase 1 while layering on successive licensing deals and equity raises. Over 2024–2026, the story progressed from heavy losses and Nasdaq issues toward somewhat improved losses and larger licensing economics, but each report has reiterated dependence on external funding and capital markets access.
Market Pulse Summary
The stock surged +262.0% in the session following this news. A strong positive reaction aligns with multiple supportive data points: Q1 2026 revenue of $6.5 million, net income of $3.5 million, and reduced R&D and G&A versus 2025. Historically, earnings averaged only a -1.61% move, so a large gain would mark a break from past patterns. Investors would need to weigh this against the explicit going-concern warning and reliance on ongoing licensing and equity financings.
Key Terms
phase 1 medical
interleukin 2 medical
il-2 medical
treg medical
car-t cell therapies medical
pre-funded warrants financial
going concern financial
AI-generated analysis. Not financial advice.
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026.
The Company remains on track to provide preliminary clinical data readout from the first two dose levels of the Phase 1 clinical study evaluating HCW9302 in alopecia areata in the first half of 2026. There are two clinical sites actively enrolling patients, and enrollment has been on schedule. HCW9302 is an injectable, first-in-kind interleukin 2 (“IL-2”) fusion protein complex designed to suppress the hair-follicle killing activities of the auto-reactive immune cells typically found in patients suffering with alopecia areata by activating and expanding regulatory T (“Treg”) cells. The Company has not reported any dose limiting toxicities in the patients treated to date. With continued patient enrollment, the full Phase 1 human data readout is expected in the fourth quarter of 2026.
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, “HCW9302 was selected as the lead product candidate for the Company’s autoimmune program because it has demonstrated relatively high IL-2Rα affinity and sustains serum exposure, which implies it has a strong profile for the treatment of autoimmune disorders. The Company’s preclinical studies in nonhuman primates show that HCW9302 achieves significantly longer serum half-life and exhibits strong biological activity in relatively low doses, which could appear in the human data readout as support for enhanced receptor selectivity, better tolerability and reduced off-target effects.”
Business Highlights
Transaction Closed for Exclusive Worldwide License for HCW11-006
On March 16, 2026, the closing for the licensing arrangement with Beijing Trimmune Biotech Co., Ltd (“Trimmune”) occurred upon receipt of the full nonrefundable upfront license fee. The Trimmune upfront license fee consisted of
Commercial-Ready Molecules Used as Reagents
On March 13, 2026, Science Advances, a peer-reviewed, high-impact journal, released a publication with the Company’s data that showed the Company’s proprietary, commercial-ready compound, HCW9206, could fundamentally change how CAR-T cell therapies are manufactured and potential improve their clinical efficacy against diseases such as cancer and HIV. These findings support the Company’s belief that HCW9206 is a leap forward in both clinical potential and manufacturing efficiency. The Company is actively seeking a corporate partner to commercialize the reagent program.
February 2026 Equity Offering
On February 19, 2026, the Company completed a
First Quarter 2026 Financial Results
Revenues: Revenues for the three months ended March 31, 2025 and 2026 were
Research and development (R&D) expenses: R&D expenses for the three months ended March 31, 2025 and 2026 were
General and administrative (G&A) expenses: G&A expenses for the three months ended March 31, 2025 and 2026 were
Legal expenses (recoveries), net: Legal expenses and recoveries, net represent the legal fees that the Company incurred for an Arbitration, net of insurance recoveries. In the three months ended March 31, 2025, the Company received a
Net income (loss): Net income (loss) for the three months ended March 31, 2025 and 2026 were a loss of
Financial Guidance
As of March 31, 2026, the Company believes that substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support. We considered future elements of our financing plan, especially business development programs. We have had early success in completing key elements of our multi-step financing plan; however, we cannot be assured that we will continue to have success with remaining elements of our plan.
On May 5, 2026, the Company was granted a Hearing to appeal a determination by the Nasdaq Listing Qualifications Staff (the “Staff”) to delist the Company’s securities from The Nasdaq Capital Market (“Nasdaq”) due to the Company’s non-compliance with the
About HCW Biologics
HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Forward Looking Statements
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including timing and efficacy in human clinical trial data for HCW9302, correlation of primate studies to potential data from the clinical trial, and the ability of HCW9206 to increase efficacy in CAR-T programs. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 31, 2026, the Form 10-Q filed with the SEC on May 14, 2026, and in other filings filed from time to time with the SEC. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
| HCW Biologics Inc. | ||||||||
| Condensed Statements of Operations | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2025 | 2026 | |||||||
| Revenues: | ||||||||
| Revenues | $ | 5,065 | $ | 6,543,001 | ||||
| Cost of revenues | (4,052 | ) | (11,071 | ) | ||||
| Net revenues | 1,013 | 6,531,930 | ||||||
| Operating expenses: | ||||||||
| Research and development | 1,478,711 | 1,257,948 | ||||||
| General and administrative | 2,227,597 | 1,833,277 | ||||||
| Legal expenses, net | (1,739,493 | ) | 6,850 | |||||
| Indirect tax expense | — | 198,146 | ||||||
| Total operating expenses | 1,966,815 | 3,296,221 | ||||||
| Operating income (loss) | (1,965,802 | ) | 3,235,709 | |||||
| Interest expense | (255,822 | ) | (109,274 | ) | ||||
| Change in fair value of warrant liability | — | 667,343 | ||||||
| Other income, net | 24,749 | 8,888 | ||||||
| Net income (loss) before income taxes | $ | (2,196,875 | ) | $ | 3,802,666 | |||
| Income tax expense | — | (330,186 | ) | |||||
| Net income (loss) | $ | (2,196,875 | ) | $ | 3,472,480 | |||
| Equity dividend to investor | — | (1,488,472 | ) | |||||
| Net income (loss) attributable to Common Stockholders | $ | (2,196,875 | ) | $ | 1,984,008 | |||
| Net income (loss) per share, basic and diluted | $ | (1.97 | ) | $ | 0.37 | |||
| Weighted average shares outstanding, basic and diluted | 1,116,891 | 5,425,871 | ||||||
| HCW Biologics Inc. | ||||||||
| Condensed Balance Sheets | ||||||||
| December 31, | March 31, | |||||||
| 2025 | 2026 | |||||||
| Unaudited | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,952,464 | $ | 1,228,879 | ||||
| Accounts receivable, net | 32,175 | 74,844 | ||||||
| Prepaid expenses | 222,156 | 297,760 | ||||||
| Other current assets | 77,564 | 119,843 | ||||||
| Total current assets | 2,284,359 | 1,721,326 | ||||||
| Investments | 1,326,329 | 4,826,329 | ||||||
| Property, plant and equipment, net | 20,880,849 | 20,766,082 | ||||||
| Other assets | 28,476 | 28,476 | ||||||
| Total assets | $ | 24,520,013 | $ | 27,342,213 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Liabilities | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 13,143,394 | $ | 11,785,980 | ||||
| Accrued liabilities and other current liabilities | 1,110,104 | 1,125,639 | ||||||
| Short-term debt, net | 6,809,215 | 6,577,194 | ||||||
| Deferred Revenue | — | 470,000 | ||||||
| Total current liabilities | 21,062,713 | 19,958,813 | ||||||
| Warrant liability | 928,435 | |||||||
| Contingent liability | 692,531 | 692,531 | ||||||
| Total liabilities | 21,755,244 | 21,579,779 | ||||||
| Stockholders’ equity: | ||||||||
| Common stock: | ||||||||
| Common, | 328 | 673 | ||||||
| Additional paid-in capital | 111,280,287 | 110,805,127 | ||||||
| Accumulated deficit | (108,515,846 | ) | (105,043,366 | ) | ||||
| Total stockholders’ equity | 2,764,769 | 5,762,434 | ||||||
| Total liabilities and stockholders’ equity | $ | 24,520,013 | $ | 27,342,213 | ||||
